[{"id":"cb935a08-f353-4653-b5c2-b1bea0cd347d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05538572","created_at":"2022-09-14T18:56:05.720Z","updated_at":"2024-07-02T16:35:23.135Z","phase":"Phase 1","brief_title":"A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05538572","lead_sponsor":"Prelude Therapeutics","biomarkers":" HER-2 • KRAS • ER • TP53 • CDKN2A • CDKN2B","pipe":" | ","alterations":" KRAS mutation • ER positive • HER-2 negative • TP53 wild-type • CDKN2A deletion • RAS wild-type • SMARCA4 mutation • IDH wild-type","tags":["HER-2 • KRAS • ER • TP53 • CDKN2A • CDKN2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • ER positive • HER-2 negative • TP53 wild-type • CDKN2A deletion • RAS wild-type • SMARCA4 mutation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PRT3645"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 12/27/2022","start_date":" 12/27/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-01-17"}]